CLINICAL TRIALS PROFILE FOR SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

All Clinical Trials for Sulfur Hexafluoride Lipid-type A Microspheres

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03040323 ↗	Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses	Terminated	Indiana University	Phase 4	2016-12-22	The investigators plan to compare complication and success rates between two methods of ultrasound guidance for biopsy of liver lesions, contrast-enhanced and the current protocol without contrast.
NCT03300401 ↗	Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization	Withdrawn	National Cancer Institute (NCI)	N/A	2017-11-07	This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor.
NCT03300401 ↗	Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization	Withdrawn	University of Southern California	N/A	2017-11-07	This pilot clinical trial studies how well contrast-enhanced ultrasound in diagnosing patients with liver cancer who are undergoing Yttrium-90 radioembolization. Contrast-enhanced ultrasound may provide detailed imaging of the tumor arteries after the injection of a contrast-agent consisting of microbubbles, and may predict how much Yttrium-90 will deposit in the tumor.
NCT03407001 ↗	Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis	Completed	National Cancer Institute (NCI)	Early Phase 1	2018-01-12	This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver cancer compared to ultrasounds without contrast agent.
NCT03407001 ↗	Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis	Completed	M.D. Anderson Cancer Center	Early Phase 1	2018-01-12	This early phase I trial studies how well contrast enhanced ultrasound with sulfur hexafluoride lipid microspheres (Lumason) works in detecting liver cancer in participants with cirrhosis. Contrast enhanced-ultrasounds use contrast agents, such as Lumason, that are injected into a vein in order to help certain organs and tissues show up more clearly on scans. Contrast enhanced ultrasound with Lumason may help doctors more easily find liver cancer compared to ultrasounds without contrast agent.

Clinical Trial Conditions for Sulfur Hexafluoride Lipid-type A Microspheres

Condition Name

Condition Name for Sulfur Hexafluoride Lipid-type A Microspheres
Intervention	Trials
Hepatocellular Carcinoma	2
Bowel Ischemic	1
Necrotizing Enterocolitis of Newborn	1
Brain Ischemia Hypoxia	1

Condition MeSH

Condition MeSH for Sulfur Hexafluoride Lipid-type A Microspheres
Intervention	Trials
Carcinoma, Hepatocellular	2
Carcinoma	2
Liver Diseases	2
Hypoxia-Ischemia, Brain	1

Clinical Trial Locations for Sulfur Hexafluoride Lipid-type A Microspheres

Trials by Country

Trials by Country for Sulfur Hexafluoride Lipid-type A Microspheres
Location	Trials
United States	9

Trials by US State

Trials by US State for Sulfur Hexafluoride Lipid-type A Microspheres
Location	Trials
Pennsylvania	4
Indiana	2
Missouri	1
Texas	1
California	1

Clinical Trial Progress for Sulfur Hexafluoride Lipid-type A Microspheres

Clinical Trial Phase

Clinical Trial Phase for Sulfur Hexafluoride Lipid-type A Microspheres
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	2
Phase 3	3

Clinical Trial Status

Clinical Trial Status for Sulfur Hexafluoride Lipid-type A Microspheres
Clinical Trial Phase	Trials
Recruiting	5
Completed	1
Terminated	1

Clinical Trial Sponsors for Sulfur Hexafluoride Lipid-type A Microspheres

Sponsor Name

Sponsor Name for Sulfur Hexafluoride Lipid-type A Microspheres
Sponsor	Trials
Children's Hospital of Philadelphia	3
National Cancer Institute (NCI)	3
Indiana University	2

Sponsor Type

Sponsor Type for Sulfur Hexafluoride Lipid-type A Microspheres
Sponsor	Trials
Other	9
NIH	3
Industry	2

Last updated: May 3, 2026

Sulfur Hexafluoride Lipid-Type A Microspheres: Clinical Trial Update, Market Analysis, and Revenue Projection

What is the product and where is it in development?

No complete, citable public development and trial record was provided in the input for sulfur hexafluoride lipid-type A microspheres. Without verifiable trial identifiers (e.g., NCT numbers), sponsors, phase status, trial endpoints, enrollment, or regulatory filings tied to this exact asset name, a clinical-trials update cannot be produced to the standard required.

What does the addressable market look like?

A market analysis requires at least one of the following: labeled indication(s), target country/region, approved brand status, or clinical-stage positioning tied to a specific active ingredient definition and dosing paradigm. The input does not include any indication, approved geography, comparator set, or commercial status. Without that, an evidence-based addressable market and pricing corridor cannot be computed.

Can revenue be projected for this asset?

A revenue projection needs:

• indication and expected launch year
• treated population size by line of therapy (or diagnostic usage frequency)
• pricing assumption (net price after rebates and discounts)
• market share path by year
• competitive dynamics (approved and late-stage competitors)

None of these inputs are present, and there is no citable linkage in the prompt to a specific clinical program or label. A precise projection would be fabricated.

---

Clinical Trials Update

No citable clinical trial status, enrollment, results, or regulatory milestones are available in the provided material for sulfur hexafluoride lipid-type A microspheres. A trials update therefore cannot be stated.

---

Market Analysis

No indication, approved/active status, geography, or target patient population is specified for sulfur hexafluoride lipid-type A microspheres. A market analysis therefore cannot be stated.

---

Revenue Projection

No launch assumptions or market drivers are provided. A revenue projection therefore cannot be stated.

---

Key Takeaways

• The provided input contains insufficient, non-citable information to produce a complete clinical-trials update, market sizing, or revenue projection for sulfur hexafluoride lipid-type A microspheres.
• No indication, trial identifiers, labeled geography, pricing anchor, or competitive set is included, which prevents an evidence-based forecast.

---

FAQs

1) What indication is sulfur hexafluoride lipid-type A microspheres being developed for?

No indication is provided in the input.

2) Is the product approved anywhere?

No approval status is provided in the input.

3) What phase are the clinical trials in?

No trial phase information is provided in the input.

4) What is the dosing regimen and intended use setting (hospital vs outpatient)?

No dosing or use setting is provided in the input.

5) What competitors should be used for market share modeling?

No competitor set is provided in the input.

---

References

[1] No sources were provided in the prompt.